---
title: "Here’s How Much You Would Have Made Owning argenx Stock In The Last 5 Years"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295451566.md"
description: "argenx (NASDAQ:ARGX) has outperformed the market over the past five years with an annualized return of 22.73%, exceeding the market by 11.1%. The company currently holds a market capitalization of $54.18 billion. An initial investment of $1,000 in ARGX five years ago would be worth approximately $2,787.97 today, highlighting the power of compounded returns."
datetime: "2026-08-10T20:45:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295451566.md)
  - [en](https://longbridge.com/en/news/295451566.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295451566.md)
generator: "portal-rs"
---

# Here’s How Much You Would Have Made Owning argenx Stock In The Last 5 Years

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 11.1% on an annualized basis producing an average annual return of 22.73%. Currently, argenx has a market capitalization of $54.18 billion.

**Buying $1000 In ARGX:** If an investor had bought $1000 of ARGX stock 5 years ago, it would be worth **$2,787.97** today based on a price of $866.11 for ARGX at the time of writing.

### argenx’s Performance Over Last 5 Years

![comp_fig](https://imageproxy.pbkrs.com/https://cdn.benzinga.com/files/images/story/2026/08/10/cc6d2105a09520c471acf411a1df1b41.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what’s the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

*This article was generated by Benzinga's automated content engine and reviewed by an editor.*

### Related Stocks

- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)

## Related News & Research

- [argenx (ENXTBR:ARGX) Hits A Phase 3 Win, Is The Upside Fully Priced?](https://longbridge.com/en/news/296529685.md)
- [$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296119451.md)
- [Argenx Says Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis Met Primary Endpoint](https://longbridge.com/en/news/296059044.md)
- [These Analysts Boost Their Forecasts On Argenx](https://longbridge.com/en/news/296226998.md)
- [ARGX: Efgartigimod achieved significant, sustained improvement in autoimmune myositis in Phase 3](https://longbridge.com/en/news/296061848.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**